Valvular Heart Disease: Pathophysiology, Clinical Manifestations, and Management

Valvular heart disease represents a diverse group of cardiac pathologies affecting the heart's four valves: aortic, mitral, tricuspid, and pulmonary. These conditions can result from congenital abnormalities, degenerative processes, infectious causes, or rheumatic disease. The two primary hemodynamic consequences are stenosis (narrowed valve opening) and regurgitation/insufficiency (inadequate valve closure).

Classification by Etiology:

• Degenerative: Age-related calcification, myxomatous degeneration
• Rheumatic: Post-infectious autoimmune response to Group A Streptococcus
• Infectious: Endocarditis causing valve destruction
• Congenital: Bicuspid aortic valve, mitral valve prolapse
• Ischemic: Papillary muscle dysfunction or rupture

Hemodynamic Principles: Stenotic valves create pressure gradients across the valve, leading to chamber hypertrophy proximal to the obstruction. The severity is assessed using mean gradients (aortic stenosis: severe >40 mmHg) and valve areas (aortic stenosis: severe <1.0 cm²). Regurgitant valves cause volume overload, leading to chamber dilatation and eventual heart failure.

Clinical Assessment Framework: Evaluation involves careful history-taking for symptom progression, physical examination for characteristic murmurs and signs of heart failure, electrocardiography for chamber enlargement patterns, and echocardiography as the gold standard for quantitative assessment. The timing of intervention depends on symptom severity, left ventricular function, and specific anatomical considerations.

Compensatory Mechanisms: The heart initially compensates through chamber remodeling: concentric hypertrophy in stenosis and eccentric hypertrophy in regurgitation. Understanding these adaptive responses is crucial for timing interventions before irreversible myocardial damage occurs.

Aortic stenosis (AS) is characterized by obstruction of left ventricular outflow due to impaired aortic valve opening. The most common cause in adults >65 years is degenerative calcification, while bicuspid aortic valves predominate in younger patients. Rheumatic heart disease remains significant in developing countries.

Pathophysiologic Cascade: Progressive valve narrowing increases left ventricular (LV) afterload, leading to concentric hypertrophy to maintain stroke volume. Initially, this compensation preserves cardiac output, but eventually leads to diastolic dysfunction, reduced coronary perfusion, and heart failure. The normal aortic valve area of 3-4 cm² becomes critically stenotic at <1.0 cm².

Classical Symptom Triad:

1. Exertional dyspnea: Earliest symptom due to elevated LV filling pressures
2. Angina pectoris: Results from increased myocardial oxygen demand exceeding supply
3. Syncope: Caused by inability to increase cardiac output during exertion

Physical Examination Findings:

• Murmur: Harsh, crescendo-decrescendo systolic murmur at right upper sternal border, radiating to carotids
• Pulse character: Pulsus parvus et tardus (weak, delayed carotid upstroke)
• Apex beat: Sustained, non-displaced (until late stages)
• Heart sounds: Soft or absent A2, possible S4 gallop

Severity Grading:

Natural History: Asymptomatic patients have excellent prognosis with <1% annual mortality. However, symptom onset dramatically changes prognosis: average survival is 2-3 years with heart failure, 3-5 years with syncope, and 5 years with angina without intervention.

Mitral regurgitation (MR) occurs when the mitral valve fails to close properly during systole, allowing retrograde blood flow from the left ventricle into the left atrium. Understanding the functional anatomy of the mitral valve apparatus is essential for comprehending the various etiologies.

Mitral Valve Apparatus Components:

• Leaflets: Anterior (larger) and posterior
• Annulus: Fibrous ring providing structural support
• Chordae tendineae: Fibrous cords connecting leaflets to papillary muscles
• Papillary muscles: Anterolateral and posteromedial muscles
• Left ventricular wall: Provides papillary muscle attachment

Classification by Mechanism:

Primary (Organic) MR:

• Degenerative: Mitral valve prolapse, myxomatous degeneration, leaflet perforation
• Rheumatic: Leaflet thickening, commissural fusion, chordal shortening
• Infectious: Endocarditis with vegetation or perforation
• Congenital: Cleft mitral valve, parachute mitral valve

Secondary (Functional) MR:

• Ischemic: Papillary muscle dysfunction or rupture
• Cardiomyopathy: LV dilatation with annular dilatation and leaflet tethering

Hemodynamic Consequences: MR creates volume overload of both the left ventricle and left atrium. The LV develops eccentric hypertrophy to accommodate increased preload, while the LA enlarges to handle the regurgitant volume. Chronic adaptation maintains forward cardiac output initially, but eventual LV dysfunction and pulmonary hypertension develop.

Clinical Presentation: Acute MR presents with sudden onset heart failure and pulmonary edema due to lack of LA compliance. Chronic MR has an insidious onset with gradual exercise intolerance, fatigue, and eventually signs of right heart failure. The characteristic murmur is a holosystolic murmur heard best at the apex, radiating to the axilla.

Severity Assessment:

• Mild: Regurgitant volume <30 mL, regurgitant fraction <30%
• Moderate: Regurgitant volume 30-59 mL, regurgitant fraction 30-49%
• Severe: Regurgitant volume ≥60 mL, regurgitant fraction ≥50%

Rheumatic heart disease (RHD) results from an autoimmune response following Group A Streptococcal pharyngitis, leading to acute rheumatic fever (ARF) and subsequent chronic valvular damage. Despite declining incidence in developed countries, RHD remains a significant cause of morbidity and mortality in developing nations, affecting an estimated 15-20 million people worldwide.

Pathogenetic Mechanism: Molecular mimicry between streptococcal M proteins and human cardiac proteins triggers cross-reactive antibodies that attack cardiac tissue. The autoimmune response primarily affects the mitral and aortic valves, causing both acute inflammation and chronic fibrotic changes.

Jones Criteria for ARF Diagnosis:

Major Criteria:

• Carditis: Pancarditis affecting pericardium, myocardium, and endocardium
• Polyarthritis: Migratory large joint involvement
• Chorea: Sydenham's chorea (involuntary movements)
• Erythema marginatum: Characteristic rash with raised borders
• Subcutaneous nodules: Painless nodules over bony prominences

Minor Criteria:

• Fever ≥38.5°C
• Arthralgia
• Elevated acute phase reactants (ESR >60 mm/h, CRP >3.0 mg/dL)
• Prolonged PR interval

Valvular Pathology: Chronic RHD causes characteristic valvular changes:

• Commissural fusion: Leading to stenosis
• Leaflet thickening and retraction: Causing regurgitation
• Chordal shortening and fusion: Restricting leaflet mobility
• Calcification: Late-stage changes increasing severity

Mitral Valve Involvement: Most commonly affected valve (75-85% of cases). Rheumatic mitral stenosis creates a characteristic "fish mouth" or "buttonhole" opening. The pathognomonic finding is commissural fusion with preserved leaflet mobility, distinguishing it from degenerative disease.

Aortic Valve Involvement: Usually occurs in combination with mitral disease. Rheumatic aortic regurgitation results from leaflet retraction and commissural fusion. Isolated rheumatic aortic stenosis is rare.

Clinical Course: RHD follows a biphasic pattern: acute phase (ARF) followed by a latent period of 10-30 years before chronic valvular complications manifest. Secondary prophylaxis with penicillin is essential to prevent recurrent ARF and progression of valvular disease.

Prosthetic valve replacement has revolutionized the treatment of severe valvular disease, offering life-saving therapy for patients with symptomatic stenosis or regurgitation. The choice between mechanical and biological valves depends on patient age, anticoagulation tolerance, lifestyle factors, and valve-specific considerations.

Mechanical Valves:

Types:

• Ball-and-cage: Starr-Edwards (rarely used today)
• Tilting-disk: Björk-Shiley, Medtronic Hall
• Bileaflet: St. Jude Medical, ATS (most common current design)

Advantages:

• Excellent durability (20-30 year lifespan)
• Low structural deterioration rates
• Suitable for young patients

Disadvantages:

• Lifelong anticoagulation requirement (INR 2.5-3.5 for aortic, 3.0-4.0 for mitral)
• Risk of thromboembolism and bleeding
• Audible clicking sounds

Biological Valves:

Types:

• Xenografts: Porcine (Hancock, Carpentier-Edwards) or bovine pericardial
• Homografts: Human donor valves
• Autografts: Ross procedure (pulmonary autograft)

Advantages:

• No long-term anticoagulation (except first 3 months)
• Silent operation
• Better hemodynamics

Disadvantages:

• Limited durability (10-15 years)
• Structural valve deterioration
• Need for reoperation

Anticoagulation Management:

Prosthetic Valve Complications:

Early (<30 days):

• Bleeding
• Thromboembolism
• Paravalvular leak
• Valve dysfunction

Late (>30 days):

• Prosthetic valve endocarditis
• Structural valve deterioration
• Pannus formation
• Patient-prosthesis mismatch

Surveillance: Baseline echocardiogram within 30 days post-operatively, then annually or when symptoms develop. Key parameters include gradients, valve area, and regurgitation severity.

Accurate diagnosis of valvular heart disease requires a systematic approach combining clinical assessment, electrocardiography, chest radiography, and echocardiography. Advanced imaging modalities provide additional anatomical and functional information for complex cases.

Electrocardiographic Findings:

Aortic Stenosis:

• Left ventricular hypertrophy (Sokolow-Lyon criteria)
• Left axis deviation
• ST-T wave changes (strain pattern)
• Left atrial enlargement in advanced cases

Mitral Regurgitation:

• Left atrial enlargement (P mitrale)
• Left ventricular hypertrophy (volume overload pattern)
• Atrial fibrillation in chronic cases

Chest Radiography: Provides information about chamber enlargement, pulmonary vascular congestion, and valve calcification:

• Aortic stenosis: Post-stenotic aortic dilatation, LV enlargement
• Mitral regurgitation: LA and LV enlargement, pulmonary vascular redistribution

Echocardiographic Assessment:

Two-Dimensional Imaging:

• Valve morphology and mobility
• Chamber dimensions and wall thickness
• Left ventricular function assessment

Doppler Techniques:

• Continuous wave: Peak and mean gradients across stenotic valves
• Color flow: Regurgitant jets and their severity
• Pulse wave: Filling patterns and diastolic function

Advanced Imaging Modalities:

Cardiac Magnetic Resonance (CMR):

• Accurate quantification of regurgitant volumes
• Assessment of ventricular function and mass
• Evaluation of myocardial fibrosis
• Superior to echocardiography for right-sided valves

Cardiac Catheterization:

• Direct pressure measurements
• Assessment of coronary artery disease
• Evaluation when echocardiography is inconclusive
• Hemodynamic assessment of multiple valve disease

CT Imaging:

• Valve calcification scoring
• Annular sizing for transcatheter procedures
• Assessment of aortic dimensions

Exercise Testing: Valuable for asymptomatic patients with severe disease:

• Unmasks symptoms in apparently asymptomatic patients
• Assesses functional capacity objectively
• Evaluates blood pressure response
• Guides timing of intervention in borderline cases

Biomarkers: BNP and NT-proBNP levels correlate with symptom severity and provide prognostic information, particularly useful in asymptomatic patients with severe disease.

Management of valvular heart disease involves medical therapy for symptom relief and complications, timing of surgical intervention, and choice of surgical procedure. The goal is to intervene before irreversible ventricular dysfunction occurs while avoiding unnecessary early surgery.

Medical Management:

Heart Failure Treatment:

• ACE inhibitors/ARBs: Reduce afterload in MR, contraindicated in severe AS
• Beta-blockers: Improve diastolic filling, use cautiously in severe AS
• Diuretics: Symptom relief for volume overload
• Digoxin: Rate control in atrial fibrillation

Anticoagulation:

• Atrial fibrillation (CHA2DS2-VASc score-based)
• Mechanical prosthetic valves (lifelong)
• Biological valves (3 months post-operatively)

Surgical Indications:

Aortic Stenosis:

• Class I (definite):
  • Symptomatic severe AS
  • Severe AS undergoing cardiac surgery
  • Severe AS with LVEF <50%
• Class IIa (reasonable):
  • Asymptomatic severe AS with abnormal exercise test
  • Very severe AS (velocity >5 m/s)

Mitral Regurgitation:

• Primary MR:
  • Symptomatic severe MR
  • Asymptomatic severe MR with LVEF ≤60% or LVESD ≥40 mm
  • High likelihood of repair success
• Secondary MR:
  • Severe MR despite optimal medical therapy
  • Undergoing CABG with moderate-severe MR

Surgical Options:

Valve Repair vs. Replacement:

Transcatheter Interventions:

TAVR (Transcatheter Aortic Valve Replacement):

• Initially for high-risk patients
• Now approved for intermediate and low-risk patients
• Approaches: transfemoral, transapical, transaortic
• Complications: conduction abnormalities, paravalvular leak

MitraClip:

• Edge-to-edge repair for high-risk MR patients
• Reduces MR severity and improves symptoms
• Lower procedural risk than surgery

Timing Considerations: Optimal timing balances symptom relief against operative risk and prosthetic valve complications. Regular monitoring with echocardiography and clinical assessment is essential for asymptomatic patients with severe disease.